OMS Grade II Glioma
Conditions
Keywords
Glioma, Neurocognitive functions
Brief summary
This is a multicenter prospective study:2 independant cohorts of patients with OMS grade II glioma will be followed during 5 years. * cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy) * cohort B: patients with disease simple monitoring. The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.
Interventions
BEHAVIORALneurocognitive tests
* inclusion * 1 year * 3 years * 5 years
Sponsors
Ministry of Health, France
Centre Leon Berard
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* OMS grade II glioma * signed informed consent * age \>=18 * IK \>=80% * ability to read, write and undertand French
Exclusion criteria
* glioma localized to brainstem * other neurologic or psychiatric disease * history of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization * neuroleptic concomitant treatment * pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MoCA test | 36 months |
Countries
France
Outcome results
None listed